Novartis Secures Prostate Cancer Treatment With Endocyte Deal
Novartis Oncology

Endocyte Inc. (ECYT) agreed to be acquired by Swiss drugs giant Novartis AG (NVS) for $2.1 billion.

The deal values the developer of cancer treatments at $24 a share, a 54% premium to Endocyte's closing price on Wednesday of $15.56.

Novartis will get its hands on Endocyte's promising Lu-PSMA-617, a radioligand treatment that targets prostate cancer by attaching radioactive Lutetium to cancerous cells.

"The proposed acquisition of Endocyte builds on our growing capability in radio-pharmaceuticals, which is expected to be an increasingly important treatment option for patients and a key growth driver for our business," said Novartis Oncology CEO Liz Barrett in a statement. "We are also excited about the opportunity to break into the prostate cancer arena with a near-term product that has the potential to make a meaningful impact for patients in great need of more options."

Endocyte shares rose more than 50% in premarket trading on Thursday to $23.39.

This story first appeared on TheStreet's sister site, The Deal, on Thursday.

More from Investing

How Vulnerable the U.S. Economy Is -- Recession Watch

How Vulnerable the U.S. Economy Is -- Recession Watch

Market Handles Negative News as Holiday Spirit Takes Hold

Market Handles Negative News as Holiday Spirit Takes Hold

Nissan Says Chairman Carlos Ghosn Arrested, Misconduct 'Unacceptable, Serious'

Nissan Says Chairman Carlos Ghosn Arrested, Misconduct 'Unacceptable, Serious'

Anything Short of Escalation Is a Win in This Trade War: Market Recon

Anything Short of Escalation Is a Win in This Trade War: Market Recon

JD.com Slides After Q3 Revenues Miss Forecasts For China-Based Online Retailer

JD.com Slides After Q3 Revenues Miss Forecasts For China-Based Online Retailer